In this episode, Professor Michael Hofman shares his experience with PSMA theranostics trials in prostate cancer, particularly focusing on the ProPSMA and TheraP trials.
He emphasises the advancements in PSMA PET imaging, highlighting its prognostic and predictive significance, as well as the importance of accurate imaging in guiding treatment decisions.
He also addresses the challenges of conducting imaging clinical trials and discusses the importance of industry collaboration in research.